Catenator technology induces reversible antibody catenation by fusing a weakly
homodimerizing protein to the C-terminus of IgG antibodies.

This significantly increases antigen-binding avidity, even at low antigen density,
and can enhance the performance of antibody-based applications,
from rare biomarker detection to targeted anticancer therapies